BioBehavioral Diagnostics, the Westford, MA-based maker of a tool for diagnosing attention-deficit hyperactivity disorder, said today it has raised $10 million in a Series B financing. Sevin Rosen Funds and Tullis Dickerson led the round, according to the company. BioBehavioral plans to use the cash to expand its sales and marketing efforts, and do more clinical work for its Quotient ADHD System.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
